로딩 중…
StockDiggingStockDigging

PharmGen Science, Inc.

004720· KOSPI
₩2,910-3.00%
2026-06-19

Price Chart

PharmGen Science, Inc.-33.26%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap65.92B KRW
Revenue173.52B KRW
Net Income-116.90B KRW
Total Assets199.06B KRW
Net Assets150.36B KRW
Employees254
Value
P/B0.44x
P/S0.38x
EV/EBITDA9.28x
FCF Yield-6.60%
Profitability
ROE-77.75%
ROA-58.73%
Op. Margin3.29%
Revenue Growth1.04%
Earnings Growth-3248.14%
Financial Health
Debt Ratio32.38%
Total Debt5.50B KRW
FCF-4.35B KRW
Cash18.41B KRW
Current Ratio2.90x
Net Debt/EBITDA-2.26x
Performance
1Y Return-33.26%
1M Return-18.60%
From 52W High-46.99%
1Y MDD-40.91%
Trading
Volume79,878 shares
Foreign Own.2.63%
Per Share
EPS-5,961 KRW
BPS6,862 KRW

Company Info

CEO 김혜연 박희덕(각자)
Employees 254
Founded 1966
HQ 경기 화성시, KR

Established in 1966 as Sudo Pharmaceutical Industry, this company engages in digestive system therapeutics and health functional foods. With headquarters and production facilities in Hwaseong, Gyeonggi-do, it operates wholesale and national branches, a global R&D center, and a development division, focusing on selling professional and general pharmaceuticals and new drug development. In 2021, it established a biosimilar new drug division and recruited experts, and in 2022, announced its R&D Vision 2030, aiming to become a specialized company in digestive system new drug development.